Cargando…

Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab

Toripalimab (Junshi Bioscience Co., Ltd) is a new immune checkpoint inhibitor (ICI) that targets programmed cell death protein 1 (PD-1) in various cancers, including metastatic melanoma. No neurological immune-related adverse events (n-irAEs) of toripalimab have been reported, except for neuromuscul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Huanyu, Xie, Xiaoxi, Zhang, Tianyu, Yang, Menghan, Zhou, Dong, Yang, Tianhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990884/ https://www.ncbi.nlm.nih.gov/pubmed/35401563 http://dx.doi.org/10.3389/fimmu.2022.850540

Ejemplares similares

Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
por: Zhou, Hong, et al.
Publicado: (2023)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
por: Vaddepally, Raju, et al.
Publicado: (2022)

Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma
por: Lin, Jingrong, et al.
Publicado: (2020)

Paclitaxel/toripalimab: Leucopenia and gastrointestinal reaction: case report
Publicado: (2021)

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
por: Batista-Duharte, Alexander, et al.
Publicado: (2023)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
por: Balaji, Aanika, et al.
Publicado: (2020)

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC
por: Wang, Yunchao, et al.
Publicado: (2023)

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
por: Zhang, Lin, et al.
Publicado: (2022)

Effectiveness and Safety of Toripalimab Combination Therapies for Patients With Chemo-Resistant Choriocarcinoma
por: Liu, Xiaomei, et al.
Publicado: (2022)

Flat dose regimen of toripalimab based on model-informed drug development approach
por: Li, Lili, et al.
Publicado: (2023)

Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
por: Robles-Alonso, Virginia, et al.
Publicado: (2022)

Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer
por: Wang, Hao, et al.
Publicado: (2023)

Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial
por: Wen, Zhenyu, et al.
Publicado: (2023)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Xu, Yu-Jie, et al.
Publicado: (2021)

Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report
por: Bu, Yuqing, et al.
Publicado: (2023)

Case Report: Good cardiac tolerance to Toripalimab in a CVD patient with oral melanoma
por: Pan, Wei, et al.
Publicado: (2022)

Multisystem immune-related adverse events due to toripalimab: Two cases-based review
por: Chen, Yanran, et al.
Publicado: (2022)

Toripalimab-associated diabetes mellitus: a case report from the community of Southern China
por: Zhang, Wenxin, et al.
Publicado: (2022)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
por: Liu, Jing, et al.
Publicado: (2014)

Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
por: Fu, Yang, et al.
Publicado: (2022)

Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report
por: Wu, Ying, et al.
Publicado: (2023)

How Much GAD65 Do You Have? High Levels of GAD65 Antibodies in Autoimmune Encephalitis
por: Gaspard, Nicolas
Publicado: (2020)

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022)

Treatment of Anti-GAD65 Autoimmune Encephalitis With Methylprednisolone
por: Azizi, Shayan, et al.
Publicado: (2021)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Remarkable Response of Toripalimab Combined with Chemotherapy in Sarcomatoid Carcinoma of Palatine Tonsil: A Case Report
por: Huang, Jiahuan, et al.
Publicado: (2021)

Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer
por: Yu, Wei, et al.
Publicado: (2021)

Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
por: Chen, Si-Cong, et al.
Publicado: (2023)

Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy
por: Liu, Hongchuan, et al.
Publicado: (2019)

Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis
por: Wang, QuanQiu, et al.
Publicado: (2018)

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
por: Eschweiler, Simon, et al.
Publicado: (2022)

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
por: Teng, Yi-Shan, et al.
Publicado: (2023)

Toripalimab combined with targeted therapy and chemotherapy achieves pathologic complete response in gastric carcinoma: A case report
por: Liu, Rui, et al.
Publicado: (2022)

Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial
por: Chen, Si-Yuan, et al.
Publicado: (2023)

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
por: Wei, Xiao‐Li, et al.
Publicado: (2020)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
por: Zhao, Ze-Rui, et al.
Publicado: (2021)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gor8qqciu7uhf70m8mfqnilrq1